After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...

Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative ...

According to a new comprehensive report from The Insight Partners, the Global Gastrointestinal Drugs Market is observing ...

Eli Lilly's Omvoh shows long-term efficacy against ulcerative colitis and Crohn's disease, with high rates of remission ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

According to GlobalData’s Sales and Forecast database, total sales for Tremfya are expected to reach $7.8 billion globally by 2029.

Eli Lilly has thrown its weight behind a cause beyond the traditional remit of pharma companies. | Eli Lilly has thrown its ...

Union Minister Ashwini Vaishnaw highlights India's rapid rise as a global semiconductor hub, driven by strong government initiatives, a skilled… A maker recently unveiled their latest project, the ...

J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona ...

Results from the national "Urgent Conversations" survey, announced today by Eli Lilly and Company , found that over half (60% ...